Donald L. Trump
#79,717
Most Influential Person Now
American physician
Donald L. Trump's AcademicInfluence.com Rankings
Donald L. Trumpphilosophy Degrees
Philosophy
#6241
World Rank
#9243
Historical Rank
#1508
USA Rank
Logic
#3425
World Rank
#4580
Historical Rank
#700
USA Rank
Download Badge
Philosophy
Donald L. Trump's Degrees
- Doctorate Medicine Harvard University
Why Is Donald L. Trump Influential?
(Suggest an Edit or Addition)According to Wikipedia, Donald Lynn "Skip" Trump is an American oncologist who has been the executive director and chief executive officer of the Inova Schar Cancer Institute in Falls Church, Virginia, since January 2015. He has the same first and last name as former United States President Donald Trump, but they are not related to each other.
Donald L. Trump's Published Works
Published Works
- Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. (2003) (2206)
- Vitamin D signalling pathways in cancer: potential for anticancer therapeutics (2007) (1400)
- Hypersensitivity reactions from taxol. (1990) (1093)
- Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. (1999) (1024)
- Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. (1999) (902)
- Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. (2006) (873)
- Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. (1999) (726)
- Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. (1997) (486)
- An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. (1993) (455)
- Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. (2005) (374)
- Sulforaphane-induced Cell Death in Human Prostate Cancer Cells Is Initiated by Reactive Oxygen Species* (2005) (356)
- Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. (2007) (349)
- Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. (1988) (340)
- Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. (1993) (298)
- Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. (2003) (288)
- Bladder cancer. Clinical practice guidelines in oncology. (2005) (278)
- Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2 (2004) (277)
- Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis. (2003) (268)
- Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. (1997) (241)
- Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. (1995) (218)
- High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. (1992) (209)
- Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers (2005) (197)
- The role of vitamin D in cancer prevention and treatment. (2012) (195)
- Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. (2001) (194)
- Importance of continued testicular suppression in hormone-refractory prostate cancer. (1993) (192)
- Anti-tumor activity of calcitriol: pre-clinical and clinical studies (2004) (185)
- A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. (1999) (184)
- Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer (2007) (180)
- Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. (1995) (173)
- Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. (2009) (171)
- Vitamin D: Considerations in the Continued Development as an Agent for Cancer Prevention and Therapy (2010) (169)
- High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. (2002) (169)
- Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy (2009) (167)
- High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. (1992) (162)
- 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. (1999) (160)
- Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. (2001) (157)
- Antiproliferative Effects of 1α,25-Dihydroxyvitamin D3 and Vitamin D Analogs on Tumor-Derived Endothelial Cells. (2002) (146)
- Richter's syndrome: diffuse histiocytic lymphoma in patients with chronic lymphocytic leukemia. A report of five cases and review of the literature. (1980) (145)
- Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors (2003) (143)
- Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. (1982) (143)
- Penile cancer: Clinical Practice Guidelines in Oncology. (2013) (139)
- Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. (1997) (136)
- Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. (2001) (136)
- Pharmacokinetics of high‐dose oral calcitriol: Results from a phase 1 trial of calcitriol and paclitaxel (2002) (133)
- Phase I study of taxol administered as a short i.v. infusion daily for 5 days. (1987) (130)
- Stat3 activation of NF-κB p100 processing involves CBP/p300-mediated acetylation (2006) (124)
- Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men. (2001) (123)
- Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivo. (2003) (123)
- Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. (1996) (120)
- Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. (2001) (114)
- Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. (1998) (111)
- A phase II study of taxol in patients with malignant melanoma (1991) (110)
- Phase II trial of high‐dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen‐independent prostate cancer (2006) (105)
- Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710) (2010) (105)
- Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. (2001) (100)
- Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. (1991) (98)
- Vitamin D in combination cancer treatment (2010) (97)
- RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells (2004) (97)
- Pretreatment Serum Concentrations of 25-Hydroxyvitamin D and Breast Cancer Prognostic Characteristics: A Case-Control and a Case-Series Study (2011) (97)
- Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells. (2004) (97)
- Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. (1991) (94)
- The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma: a study of calcitonin, L-dopa decarboxylase, and histaminase. (1982) (93)
- Management of primary germ cell tumors of the mediastinum. (1982) (93)
- Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study (2012) (91)
- Computational methods for detecting copy number variations in cancer genome using next generation sequencing: principles and challenges (2013) (91)
- A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid Tumors (2007) (91)
- Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. (2002) (91)
- Diffuse large cell and undifferentiated lymphomas with promiment mediastinal involvement. A poor prognoctic subset of patients with non‐Hodgkin's lymphoma (1982) (90)
- Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer (2009) (88)
- Metastatic leydig cell tumor of the testis report of three cases and review of the literature (1986) (87)
- Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. (2008) (84)
- Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort (2018) (83)
- Phase I study of vinblastine and verapamil given by concurrent iv infusion. (1985) (83)
- Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. (2010) (82)
- High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. (1989) (80)
- CYP24A1 inhibition enhances the antitumor activity of calcitriol. (2010) (79)
- 1,25D3 Enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models (2010) (78)
- Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer (2014) (77)
- Vitamin D in the prevention and treatment of prostate cancer. (1999) (76)
- Important clinical pharmacologic considerations in the use of methadone in cancer patients. (1979) (76)
- Vitamin D compounds: clinical development as cancer therapy and prevention agents. (2006) (74)
- Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation. (2006) (73)
- The Costs and Underappreciated Consequences of Research Misconduct: A Case Study (2010) (72)
- Epigenetic Silencing of CYP24 in Tumor-derived Endothelial Cells Contributes to Selective Growth Inhibition by Calcitriol* (2007) (71)
- Interleukin-6 polymorphism is associated with more aggressive prostate cancer. (2005) (70)
- Vitamin D-related Therapies in Prostate Cancer (2004) (68)
- Bladder cancer. (2013) (67)
- Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR, Department of Medicine, University of New South Wales, St. George Hospital Campus, Sydney, Australia.: Cancer 2004;10 (2004) (66)
- Factors influencing options in primary breast cancer treatment. (1987) (66)
- Pharmacokinetics of 1α,25-Dihydroxyvitamin D3 in Normal Mice after Systemic Exposure to Effective and Safe Antitumor Doses (2004) (65)
- Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium (2005) (65)
- Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. (2002) (65)
- Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. (1994) (64)
- Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. (2006) (63)
- Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. (2002) (63)
- Elevated seroprevalence of human herpesvirus 8 among men with prostate cancer. (2004) (61)
- Vitamin D in prostate cancer (2018) (60)
- Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators (2007) (60)
- A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis (1997) (60)
- Calcitriol enhances gemcitabine antitumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system (2010) (59)
- Dexamethasone Enhances 1α,25-Dihydroxyvitamin D3 Effects by Increasing Vitamin D Receptor Transcription* (2011) (58)
- Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. (2002) (57)
- Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate. (1982) (56)
- Spinal cord compression in prostate cancer (2005) (55)
- Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia (2014) (55)
- Effect of 25‐hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients (2011) (55)
- Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. (2009) (55)
- Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. (1987) (54)
- The role of vitamin D in cancer prevention and treatment. (2010) (54)
- 1α,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model (2008) (53)
- Pharmacokinetics and Tolerability of a Single Dose of DN-101, a New Formulation of Calcitriol, in Patients with Cancer (2005) (53)
- Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients (2014) (52)
- Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. (1997) (52)
- Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. (1988) (51)
- The antitumor efficacy of calcitriol: preclinical studies. (2006) (51)
- Effects of cytokines on the pituitary-adrenal axis in cancer patients. (1993) (50)
- The effect of various vitamin D supplementation regimens in breast cancer patients (2011) (50)
- Vitamin D Receptor Signaling and Cancer (2017) (50)
- Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature. (1992) (49)
- Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer. (1987) (49)
- Mechanistic Insights of Vitamin D Anticancer Effects. (2016) (49)
- Role of nongenomic activation of phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase 1/2 pathways in 1,25D3-mediated apoptosis in squamous cell carcinoma cells. (2006) (49)
- 'Sarcoidosis' and sarcoid-like lesions. Their occurrence after cytotoxic and radiation therapy of testis cancer. (1981) (48)
- 24-Hydroxylase in cancer: Impact on vitamin D-based anticancer therapeutics (2013) (48)
- Immediate hormonal therapy versus observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer: At 10 years results of EST3886. (2004) (47)
- Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. (2016) (47)
- Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer (2007) (47)
- A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors (2009) (46)
- Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer (2005) (45)
- Cross-sectional study to investigate the association between vitamin D status and cutaneous mast cell tumours in Labrador retrievers. (2011) (45)
- Vitamin D and cancer: clinical aspects. (2011) (44)
- Vitamin D receptor: a potential target for intervention. (2002) (44)
- CSF infections complicating the management of neoplastic meningitis. Clinical features and results of therapy. (1982) (44)
- Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. (1996) (43)
- Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion. (1990) (43)
- Vitamin D deficiency and insufficiency among patients with prostate cancer (2009) (43)
- Discordance between plasma calcitonin and tumor-cell mass in medullary thyroid carcinoma. (1979) (43)
- Antiproliferative effects in vitro and in vivo of 1,25-dihydroxyvitamin D3 and a vitamin D3 analog in a squamous cell carcinoma model system (1995) (41)
- Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (Calcitriol) in combination with dexamethasone for castration‐resistant prostate cancer (2010) (41)
- Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508. (1994) (41)
- Anaerobic liver abscess and intrahepatic metastases. A case report and review of the literature (1978) (41)
- An eastern cooperative oncology group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma (1994) (41)
- Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans. (1989) (41)
- Calcitriol (1,25-Dihydroxycholecalciferol) Selectively Inhibits Proliferation of Freshly Isolated Tumor-Derived Endothelial Cells and Induces Apoptosis (2006) (39)
- In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors (2008) (39)
- Massive skeletal muscle invasion by lymphoma. (1985) (39)
- Inecalcitol, an analog of 1,25D₃, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system (2013) (38)
- Computerized Tomography and Lymphangiography in Staging Testis Tumors (1981) (38)
- Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer (2005) (38)
- Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone‐refractory prostate cancer (2006) (38)
- Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma (1988) (38)
- Trastuzumab (T), paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced HER2-positive urothelial carcinoma: Results of a multi-center phase II NCI trial (2005) (37)
- Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase. (1996) (36)
- Megestrol acetate in the treatment of hormone refractory prostate cancer. (1997) (36)
- Structural variation discovery in the cancer genome using next generation sequencing: Computational solutions and perspectives (2015) (35)
- CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines (2007) (34)
- Toxicity and Response Evaluation of the Interferon Inducer Poly ICLC Administered at Low Dose in Advanced Renal Carcinoma and Relapsed or Refractory Lymphoma: A Report of Two Clinical Trials of the Eastern Cooperative Oncology Group (2004) (34)
- Ectopic adrenocorticotrophic (ACTH) syndrome and small cell carcinoma of the lung—assessment of clinical implications in patients on combination chemotherapy (1981) (33)
- Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients. (2002) (33)
- Modulation of 5-iodo-2'-deoxyuridine metabolism and cytotoxicity in human bladder cancer cells by fluoropyrimidines. (1985) (32)
- Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancer. (2013) (32)
- Differential vitamin D 24-hydroxylase/CYP24A1 gene promoter methylation in endothelium from benign and malignant human prostate (2011) (31)
- Bladder cancer. Clinical guidelines in oncology. (2006) (30)
- RANDOMIZED PHASE II EVALUATION OF CARBOPLATIN AND CHIP IN ADVANCED TRANSITIONAL CELL CARCINOMA OF THE UROTHELIUM (1990) (30)
- Clinical and biologic effects of combination therapy with gamma‐interferon and tumor necrosis factor (1992) (29)
- Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. (1992) (29)
- Early Growth Inhibition Is Followed by Increased Metastatic Disease with Vitamin D (Calcitriol) Treatment in the TRAMP Model of Prostate Cancer (2014) (28)
- Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP (2015) (28)
- A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer (2013) (27)
- Phase II study of fulvestrant (faslodex®) in castration resistant prostate cancer (2008) (27)
- Epigenetic silencing of CYP24 in the tumor microenvironment (2010) (27)
- All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes (1997) (27)
- Serum Vitamin D Metabolites in Colorectal Cancer Patients Receiving Cholecalciferol Supplementation: Correlation with Polymorphisms in the Vitamin D Genes (2013) (27)
- Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation (2005) (27)
- Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells. (2013) (26)
- Complications of hepatic arterial infusion chemotherapy. (1991) (26)
- Etoposide and very high dose cisplatin: salvage therapy for patients with advanced germ cell neoplasms. (1985) (26)
- Mortality after cure of testicular seminoma. Zagars GK, Ballo MT, Lee AK, Strom SS, Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.: J Clin Oncol 2004;22:640–7 (2004) (26)
- Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial (2002) (26)
- Regulation of motility, invasion, and metastatic potential of squamous cell carcinoma by 1α,25‐dihydroxycholecalciferol (2013) (25)
- Epidermolysis bullosa acquisita. Association with amyloidosis and multiple myeloma. (1980) (24)
- Cutaneous involvement in malignant histiocytosis. Case report and review of the literature. (1981) (24)
- Metastatic bladder cancer. Natural history, clinical course, and consideration for treatment. (1992) (24)
- 5-Azacytidine (NSC 102816) in refractory germ cell tumors (1993) (24)
- “Eight‐drugs‐in‐one‐day” chemotherapy administered before and after radiotherapy to adult patients with malignant gliomas (1989) (24)
- Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer (2008) (24)
- High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study. (1987) (24)
- Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel (2008) (24)
- Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours. (2010) (24)
- Bromide intoxication. (1976) (23)
- Retinoids in bladder, testis and prostate cancer: epidemiologic, pre-clinical and clinical observations. (1994) (23)
- IMMEDIATE HORMONAL THERAPY VS. OBSERVATION FOR NODE POSITIVE PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY AND PELVIC LYMPHADENECTOMY: A RANDOMIZED PHASE III EASTERN COOPERATIVE ONCOLOGY GROUP/INTER GROUP TRIAL (1999) (23)
- New serum biomarkers for prostate cancer diagnosis. (2014) (23)
- Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion. (1985) (23)
- A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells (2005) (22)
- 6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer (2013) (22)
- Biochemical assessment of the effects of acivicin and dipyridamole given as a continuous 72-hour intravenous infusion. (1988) (22)
- 5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889). (1998) (22)
- Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors (2004) (21)
- Calcitriol and cancer therapy: A missed opportunity (2018) (21)
- Antitumor Effects of Two Less-Calcemic Vitamin D Analogs (Paricalcitol and QW-1624F2-2) in Squamous Cell Carcinoma Cells (2007) (21)
- Androgen antagonists: Potential role in prostate cancer prevention. (2001) (21)
- Anti-proliferative effects of calcitriol on endothelial cells derived from two different microenvironments (2007) (21)
- Perioperative methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for poor risk transitional cell carcinoma of the bladder: an Eastern Cooperative Oncology Group pilot study. (1990) (21)
- Whole-genome sequencing of a malignant granular cell tumor with metabolic response to pazopanib (2015) (21)
- Clinical chemosensitization by misonidazole and related compounds: a critical evaluation. (1988) (20)
- Vitamin D Repletion Reduces the Progression of Premalignant Squamous Lesions in the NTCU Lung Squamous Cell Carcinoma Mouse Model (2015) (20)
- Choice of starting dose and escalation for phase I studies of antitumor agents (2004) (20)
- Phase II study of continuous 5-day vinblastine infusion in renal adenocarcinoma. (1984) (20)
- Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration‐resistant prostate cancer (2011) (19)
- Biological and Clinical Effects of Interferon-βser at Two Doses (1990) (19)
- Genetic variations in vitamin D‐related pathways and breast cancer risk in African American women in the AMBER consortium (2016) (19)
- Phenotype-specific CpG island methylation events in a murine model of prostate cancer. (2008) (19)
- Vitamin D and miRNAs in cancer. (2014) (19)
- The effects of L-dopa on in vitro and in vivo calcitonin release from medullary thyroid carcinoma. (1979) (18)
- Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group. (1985) (18)
- Advertising strategy (18)
- Phase II trial of misonidazole (MISO) and cyclophosphamide (CYC) in metastatic renal cell carcinoma. (1986) (18)
- Reversible increase in serum alpha-fetoprotein content associated with hepatic dysfunction during chemotherapy for seminoma. (1986) (18)
- Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole. (2000) (17)
- Serological immune responses to influenza vaccine in patients with colorectal cancer (2010) (17)
- Peroxisome Proliferator-Activated Receptor-γ Polymorphism, Body Mass and Prostate Cancer Risk: Evidence for Gene-Environment Interaction (2006) (17)
- HYDROCORTISONE (H) WITH OR WITHOUT MITOXANTRONE (M) IN MEN WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC). THE RESULTS OF CALGB 9182 (1999) (17)
- Does bone mineral density and knowledge influence health-related behaviors of elderly men at risk for osteoporosis? (2003) (17)
- Population pharmacokinetics of hydroxyurea in cancer patients (2009) (17)
- Eight-drugs-in-one-day chemotherapy in postirradiated adult patients with malignant gliomas. (1989) (17)
- Phase II Trial of Carboplatin in Soft‐Tissue Sarcoma (1990) (17)
- Diffuse large cell and undifferentiated lymphomas with prominent mediastinal involvement. (1982) (17)
- Phase ii evaluation of a combination of mitomycin C, vincristine, and cisplatin in advanced non‐small cell lung cancer (1986) (17)
- A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer (2004) (16)
- Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology Re: Do Mixed Histological Features Affect Survival Benefit from Neoadjuvant Platinum-Based Combination Chemotherapy in Patients with Locally Advanced Bladder Cancer? A Secondary Analysis of Southwest Oncology Group-Directed Intergr (2011) (16)
- Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: A randomized Phase III clinical trial (2008) (16)
- Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study. (1991) (16)
- Phase I and Pharmacologic Study of Intermittently Administered 9-Nitrocamptothecin in Patients with Advanced Solid Tumors (2004) (15)
- Impact of suboptimal neoadjuvant chemotherapy on peri‐operative outcomes and survival after robot‐assisted radical cystectomy: a multicentre multinational study (2017) (15)
- Inadvertent administration of 480 mg/m2 of cisplatin. (1989) (15)
- Isolation and genome-wide expression and methylation characterization of CD31+ cells from normal and malignant human prostate tissue (2013) (15)
- A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection. (1991) (14)
- A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy (1990) (14)
- Vitamin D Signaling Modulators in Cancer Therapy. (2016) (14)
- Altered VDR-mediated transcriptional activity in prostate cancer stroma (2007) (14)
- Gynecomastia in men following antineoplastic therapy. (1982) (14)
- Glutathione and glutathione S-transferase in benign and malignant prostate cell lines and prostate tissues. (1996) (14)
- Psychological and Personality Disturbance Among Patients with Testicular Cancer (1986) (14)
- Renal cell carcinoma: considerations for nephron-sparing surgery. (1995) (13)
- Evaluation of aminoglutethimide in stage D prostate cancer: an assessment of efficacy and toxicity in patients with tumors refractory to hormonal therapy. (1984) (13)
- Targeted therapies in the treatment of urothelial cancers. (2017) (13)
- 1α,25(OH)2D3 differentially regulates miRNA expression in human bladder cancer cells (2015) (13)
- Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: A phase II study (2005) (13)
- Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies (2005) (12)
- Chemotherapy of prostate cancer: Present and future (2003) (12)
- Bladder cancer. (2009) (12)
- Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882) (2003) (12)
- Biochemical characterization of nuclear receptors for vitamin D3 and glucocorticoids in prostate stroma cell microenvironment. (2011) (12)
- Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers (2006) (12)
- 25-Dihydroxycholecalciferol ( 1 , 25-D 3 ) Inhibits the Growth of Squamous Cell Carcinoma and Down-Modulates p 21 Waf 1 / Cip 1 in Vitro and in Vivo 1 (2000) (12)
- Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing (2016) (11)
- Anticancer effects of a plant lignan 7-hydroxymatairesinol on a prostate cancer model in vivo (2005) (11)
- Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line (2004) (11)
- A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with advanced colorectal cancer (CRC). (2006) (11)
- Quinacrine ochronosis and rheumatoid arthritis. (1976) (10)
- Characterization of Vitamin D insensitive prostate cancer cells (2007) (10)
- Monocyte fructose 1,6-bisphosphatase and cytidine deaminase enzyme activities: potential pharmacodynamic measures of calcitriol effects in cancer patients (2006) (10)
- A phase I trial of high-dose oral tamoxifen and CHOPE (2004) (10)
- Vitamin D3-induced Apoptosis of Murine Squamous Cell Carcinoma Cells (2001) (10)
- Pharmacokinetics (PK) and tolerability of DN-101, a new formulation of calcitriol, in patients with cancer (2004) (10)
- Psychological and mood disturbance associated with the diagnosis and treatment of testis cancer and other malignancies. (1990) (10)
- TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC) (2019) (9)
- Carboplatin in advanced, refractory germ cell neoplasms: a phase II Eastern Cooperative Oncology Group Study. (1987) (9)
- Interferon-alpha-n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma. (1990) (9)
- Painful gynecomastia following cytotoxic therapy for testis cancer: a potentially favorable prognostic sign? (1983) (9)
- Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises. (2016) (9)
- Phase II trial of etoposide in advanced prostate cancer. (1984) (9)
- Vitamin D3 enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk (2019) (8)
- Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation (2007) (8)
- Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885 (2004) (8)
- Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy, pain, and safety. (2010) (8)
- A dramatic, objective antiandrogen withdrawal response: case report and review of the literature (2008) (8)
- Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate (2002) (8)
- Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma. (1987) (8)
- 1,25D3 differentially suppresses bladder cancer cell migration and invasion through the induction of miR-101-3p. (2017) (8)
- Phase I clinical trial and pharmacokinetic evaluation of acodazole (NSC 305884), an imidazoquinoline derivative with electrophysiological effects on the heart. (1987) (7)
- Abstract 82: A comprehensive characterization of cholecalciferol supplementation induced changes in the vitamin D3metabolic pathway in metastatic colorectal cancer patients (2010) (7)
- Commentary on “Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer”. Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS, Massachusetts General Hospital Cancer Center, Boston, MA (2011) (7)
- Phase I and Pharmacokinetic Study of Weekly Docetaxel, Cisplatin, and Daily Capecitabine in Patients with Advanced Solid Tumors (2005) (7)
- 975: Once Weekly Oral Alendronate Prevents Bone Loss in Men on Androgen Deprivation Therapy for Prostate Cancer (2006) (7)
- The Art of Winning (1989) (7)
- Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology Group. (1990) (7)
- Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs (2010) (6)
- Biological and clinical effects of interferon-beta ser at two doses. (1990) (6)
- Trimetrexate in advanced hormone-refractory prostate cancer (1994) (6)
- Hospice benefits and phase I cancer trials. (2004) (6)
- Clinical Science Review: Ectopic Hormone Syndromes (1986) (6)
- 1,25D3 differentially suppresses bladder cancer cell migration and invasion through the induction of miR-101-3p (2017) (6)
- Millon Clinical Multiaxial Inventory (MCMI) findings among breast clinic patients after initial evaluation and at 4- or 8-month follow-up. (1988) (6)
- A Limited Sampling Method for the Estimation of Serum Calcitriol Area under the Curve in Cancer Patients (2003) (6)
- A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma (2004) (6)
- Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer (2004) (6)
- Peroxisome proliferator-activated receptor-gamma polymorphism, body mass and prostate cancer risk: evidence for gene-environment interaction. (2006) (6)
- A phase I trial of high-dose continuous-infusion hydroxyurea (2004) (6)
- Vitamin D and Angiogenesis (2011) (5)
- The case for early androgen deprivation: the data should not be ignored. (2002) (5)
- Aminoglutethimide: theoretical considerations and clinical results in advanced prostate cancer. (1988) (5)
- Nodular pneumonitis after chemotherapy for germ cell tumors. (1988) (5)
- Frequency of abnormalities of cortisol secretion and water metabolism in patients with small cell carcinoma of the lung and other malignancies. (1982) (5)
- Phase I/II dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate (1995) (5)
- Vitamin D and Acute Myeloid Leukemia (2011) (5)
- A phase II trial of CI-958 in patients with hormone-refractory prostate cancer (1999) (5)
- A phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of weekly 17-allylamino-17 demethoxygeldanamycin (17AAG, NSC-704057) in patients with advanced tumors. (2004) (5)
- Commentary on Bevacizumab plus interferonα compared with interferonα monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 (2009) (5)
- Electronic Cancer Munchausen Syndrome (1998) (5)
- Vitamin D and Cancer (2011) (4)
- Evaluation of carboplatin (NSC 241240) in patients with recurrent or metastatic renal cell carcinoma (1990) (4)
- Phase II study of amsacrine (AMSA) in previously treated patients with advanced transitional cell carcinoma of the urothelium: a National Bladder Cancer Collaborative Group A study. (1983) (4)
- Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: A phase II Hoosier Oncology Group study (2005) (4)
- Doxorubicin, vincristine, and cis-diamminedichloroplatinum (II) therapy in patients with advanced breast cancer. (1981) (4)
- 1. Sorafenib in advanced clear-cell renal-cell carcinoma (2007) (4)
- Subnormal Vitamin D Levels Are Associated with Adverse Outcome In Newly-Diagnosed Similarly-Treated Adult Acute Myeloid Leukemia (AML) Patients. (2010) (4)
- The Incidental Use of High-Dose Vitamin D3 in Pancreatic Cancer (2016) (4)
- Endocrine Complications (2020) (4)
- Inhibition of Protein Kinase CK 2 Reduces Cyp 24 a 1 Expression and Enhances 1 , 25-Dihydroxyvitamin D 3 Antitumor Activity in Human Prostate Cancer Cells (2013) (4)
- Trimetrexate in advanced renal cell carcinoma (1992) (3)
- Abstract 3434: Inecalcitol, an analogue of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. (2013) (3)
- Memorandum on Allocating Certain Scarce or Threatened Health and Medical Resources to Domestic Use (2020) (3)
- Treatment of neoplastic meningitis with intrathecal methotrexate and thiotepa (1981) (3)
- Nephrotoxicity with cisplatin and antihypertensive medications. (1982) (3)
- Targeting stat3 signaling in human prostate cancer cells using tyrosine kinase inhibitors (2004) (3)
- Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas (2004) (3)
- Evaluation of prostate specific antigen (PSA) response following abiraterone in metastatic, castration resistant prostate cancer (mCRPC) previously treated with ketoconazole compared to ketoconazole naïve patients: A retrospective review. (2014) (3)
- Evaluation of deoxycoformycin in patients with advanced renal cell carcinoma (1992) (3)
- The Anti-tumor Effects of Vitamin D in Other Cancers (2011) (2)
- Comparative analyses of trends and survival in patients with urothelial versus nonurothelial bladder carcinoma: National Cancer Database (NCDB) analysis. (2019) (2)
- Hospice Benefits and Phase I Cancer Trials [5] (multiple letters) (2004) (2)
- Early discussion of advance directives for patients with newly diagnosed cancer. (2016) (2)
- Phase II Evaluation of Menogaril in Advanced Prostate Cancer: Eastern Cooperative Oncology Group EST P-A885 (2001) (2)
- Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Widmark A, Fossa SD, Lundmo P, Damber JE, Vaage S, Damber L, Wiklund F, Klepp O, Department of Oncology, Umea University, Umea, Sweden (2003) (2)
- 1437 UNDERSTANDING AVOIDANCE, REFUSAL AND ABANDONMENT OF CHEMOTHERAPY BEFORE AND AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER (2013) (2)
- Neurologic Complications of Genitourinary Malignancies (2003) (2)
- Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H, Department of Urology, Graduate School of Medicine, Chiba University, Japan.: J Urol 2004;171:679–83 (2004) (2)
- A Rare Variant in ERF (rs144812092) Predisposes to Prostate and Bladder Cancers in an Extended Pedigree (2021) (2)
- Combined Effects of Circulating Levels of 25-Hydroxyvitamin D and Th1 and Th2 Cytokines on Breast Cancer Estrogen Receptor Status (2014) (2)
- 25(OH) Vitamin D3 Affects Acute Myeloid Leukemia Cell Proliferation (2013) (2)
- 1708 DO MIXED HISTOLOGIC FEATURES AFFECT SURVIVAL BENEFIT FROM NEO-ADJUVANT PLATINUM-BASED COMBINATION CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER? (2010) (2)
- Acute myelogenous leukemia as a late complication of the multimodality therapy for Hodgkin's disease. (1977) (2)
- Randomized trial of toremifene to reduce high grade prostatic intraepithelial neoplasia (HGPIN) prior to radical prostatectomy (RP) (2007) (2)
- Identification of therapeutic targets in angiosarcoma (2007) (2)
- Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group (2005) (2)
- Trimetrexate in advanced renal cell carcinoma. An ECOG phase II trial. (1992) (2)
- Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients. (2009) (2)
- Commentary on: "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial." Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den (2016) (2)
- Adjuvant chemotherapy for bladder cancer. Standard of care or unproven therapy? (1995) (2)
- Abstract 4946: Developing anti-angiogenic therapies for human hepatocellular cancer (HCC)- studies of suntinib in the woodchuck model of hepatitis B related HCC (2014) (1)
- The presence of the FRA12E/SMRT fragile site in the genome of prostate cancer patients is a predictor of metastatic development (2006) (1)
- A phase I/II trial of ketoconazole + calcitriol [1,25(OH)2D3] in castration-resistant prostate cancer. (2016) (1)
- Eligibility a nd R esponse G uidelines f or P hase I I C linical Trials i n A ndrogen-Indepen dent P rostate C ancer: Recommendations F rom t he P rostate-Specifi c A ntigen Working G roup (1999) (1)
- Cardiovascular risk in long-term survivors of testicular cancer (2008) (1)
- Abstract 6540: Regression of metastatic cancer and abscopal effects followingin situvaccination by cryosurgical tumor cell lysis and intratumoral immunotherapy: A case series (2020) (1)
- Characterization of Brain Metastases in Urothelial Cancers. (2020) (1)
- Exanetide and Pancreatic Cancer: A Case Report and Review of Relevant Literature (2015) (1)
- Phase II study of transdermal estradiol in androgen-independent prostate carcinoma (2005) (1)
- New drug delivery approach for the treatment of prostate cancer (preclinical results and phase I study results). (2004) (1)
- Abstract 5095: 1,25D3 inhibits migration and invasion through miR-101-3p in human bladder cancer cells (2015) (1)
- Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT. Iczkowski KA, Huang W, Mazzucchelli R, Pantazis CG, Stevens GR, Montironi R, Department of Pathology and Laboratory Medicine, University of Florida, Gainesville, FL.: Cancer 2004;100:294–9 (2004) (1)
- PHASE II CLINICAL TRIAL OF DUTASTERIDE IN CASTRATION- RECURRENT PROSTATE CANCER (2008) (1)
- The Antitumor Effects of Vitamin D in Genitourinary Cancer (2018) (1)
- in Vivo and in Vitro Waf 1 / Cip 1 Squamous Cell Carcinoma and Down-Modulates p 21 ) Inhibits the Growth of 31 , 25-Dihydroxycholecalciferol ( 1 , 25-D Updated (2000) (1)
- Interaction of vitamin D receptor and androgen receptor in human prostate cancer cell line (2004) (1)
- CHAPTER 97 – Clinical Development of Calcitriol and Calcitriol Analogs in Oncology: Progress and Considerations for Future Development* (2005) (1)
- A Festschrift in Honor of Edward M. Messing, MD, FACS (2018) (1)
- Predictors of complete pathological response (pT0) to neoadjuvant chemotherapy (NAC) in muscle-invasive bladder carcinoma (MIBC). (2014) (1)
- Ectopic hormone syndromes. (1986) (1)
- Targeting stat3 signaling in human prostate cancer cells using tyrosine kinase inhibitors. (2004) (1)
- Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study (2012) (1)
- Improved treatment results and leukoencephalopathic changes in patients with neoplastic meningitis treated with intrathecal methotrexate and thiotepa (1982) (1)
- Impact of molecular tumor board on late-stage gastrointestinal malignancies at a tertiary center. (2018) (1)
- Enhanced gemcitabine (G) exposure in combination with escalating doses of paricalcitol [19-nor-1 alpha, 25-(OH)2 D2] (P) in patients with advanced malignancies. (2010) (1)
- Interleukin-1α synergistic in vivo enhancement of cyclophosphamide- and carboplatin-mediated antitumor activity (1997) (1)
- Abstract 4625: Tumor expression of PIM kinases in renal cell carcinoma and the association with disease progression (2018) (1)
- A phase I and pharmacokinetic (PK) study of intravenous (IV) calcitriol and gefitinib assessing EGFR pharmacodynamic (PD) interactions through serial skin biopsies (2005) (1)
- Computerized tomography and lymphangiography in staging testis tumors. (1982) (1)
- 18 Vitamin D and Acute Myeloid Leukemia (2012) (0)
- Combatting the National Drug Demand and Opioid Crisis: Memorandum for the Heads of Executive Departments and Agencies, October 26, 2017 (2017) (0)
- Phase II evaluation of the AMAP, 773U82 mesylate, in pancreatic cancer (2004) (0)
- Serum and Bile 25(OH)D3 and 1,25(OH)2D3 Levels in Patients with Cancers Affecting the Gall Bladder and Biliary Duct: 232 (2012) (0)
- Abstract 5056: PIM-1 kinase regulates vitamin D receptor signaling in human renal carcinoma cells (2015) (0)
- Abstract 4280: Genome-wide expression and methylation analysis in CD31+ cells from African American and Caucasian American benign and malignant prostate tissue (2012) (0)
- Phase II trial of fulvestrant in castration resistant prostate cancer (2008) (0)
- Phase I Clinical Trial of a Combination of Dipyridamole and Acivicin Based upon Inhibition of Nucleoside Salvage1 (2006) (0)
- Abstract 5144: Low dose sorafenib delays hepatocellular cancer (HCC) development in the woodchuck model of hepatitis B related HCC (2015) (0)
- Interaction of vitamin D receptor and androgen receptor in human prostate cancer cell line. (2004) (0)
- Abstract 1190: Pretreatment with 1,25 dihydroxyvitamin D3 modulates p73 levels and activity to increase pro-apoptotic effects of cisplatin in bladder cancer (2016) (0)
- Serum 25(OH) vitamin D3 response to vitamin D3 supplementation in men with prostate cancer: Results of a randomized phase II trial. (2011) (0)
- Calcitriol and taxotere suppress bone metastases in PC-3M-luc-C6 prostate cancer mouse model as monitored by bioluminescence imaging (2008) (0)
- Abstract 1898: The effects of 1α,25-dihydroxyvitamin D3 (calcitriol) on the tumorigenesis of lung squamous cell carcinoma (2010) (0)
- Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing (2016) (0)
- Modulation of 06-Alkylguanine-DNA Alkyltransferase-mediated Carmustine Resistance Using Streptozotocin: A Phase I Trial1 (2006) (0)
- Abstract 238: Vitamin D sufficiency slows the progression of dysplasic lesions in the NTCU mouse model of lung squamous cell carcinoma (2014) (0)
- Abstract B07: Ratio of plasma 1,25(OH)2D to 25(OH)D is inversely associated with aggressive prostate cancer in African Americans in the North Carolina-Louisiana Prostate Cancer Project (PCaP) (2014) (0)
- A single-center experience of chemotherapy for muscle-invasive bladder cancer after radical cystectomy. (2012) (0)
- Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) (2005) (0)
- Abstract B33: Genome-wide methylation analyses reveal racial differences in blood DNA of prostate cancer patients from the North Carolina-Louisiana Prostate Cancer Project (PCaP) cohort. (2012) (0)
- Use of vitamin D derivatives to enhance the effect of cytotoxic materials (1998) (0)
- A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases (2005) (0)
- In vivo function of vitamin D receptor (VDR) in tumor angiogenesis (2007) (0)
- Use of vitamin D derivatives for enhancing the effect of cytotoxic agents (1998) (0)
- Sequential 5-fluorouracil, methotrexate, and calcium leucovorin in metastatic colorectal cancer. (1988) (0)
- Abstract LB-12: Plasma 25-hydroxyvitamin D levels are associated with aggressive prostate cancer among African Americans in the North Carolina-Louisiana Prostate Cancer Project (PCaP). (2013) (0)
- Phase I study of combination therapy with platinum analogues: Cis-platin (CDDP) and carboplatin (CBDCA) (1985) (0)
- Vitamin D and cance (2013) (0)
- Abstract 866: Delineation of novel CYP24A1 transcriptional regulators (2016) (0)
- Abstract 1819: Over-expression of PIM1 kinase contributes to CYP24A1 gene up-regulation in prostate cancer. (2013) (0)
- Phase I II S tudy o f I nterferon A lfa-NL a s A djuvant T reatment for R esectable R enal C ell C arcinoma: A n E astern C ooperative Oncology G roup/Intergroup T rial (2003) (0)
- Commentary on Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma (2009) (0)
- Gemcitabine, docetaxel and carboplatin triplet: a phase I dose-finding study with and without filgrastim (G-CSF) support (2001) (0)
- A single-center experience of chemotherapy for muscle-invasive bladder cancer after radical cystectomy. (2012) (0)
- Book reviews (2004) (0)
- Abstract 5123: 1,25D3regulates cell-matrix and cell-cell adhesion and reduces experimental metastasis in a squamous cell carcinoma model system (2010) (0)
- 61 – Endocrine Complications (2014) (0)
- Abstract 1606: Antitumor effects of vitamin D in a carcinogen-induced mouse model of lung cancer (2012) (0)
- Pharmacokinetics andTolerability of a Single Dose of DN-101 , a New Formulation of Calcitriol , in Patientswith Cancer (2005) (0)
- Abstract LB-477: Micro-RNA expression patterns to classify prostate cancer risk (2012) (0)
- Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide, and cisplatin chemotherapy for high risk clinical Stage I nonseminomatous germ cell tumors of the testis (2008) (0)
- Abstract 2226: Loss of STAG2 in bladder cancer (2014) (0)
- Patient attendance at molecular tumor board: A new means of shared decision making? (2019) (0)
- Abstract 806: SNPs in vitamin D-related genes are associated with prostate cancer aggressiveness in the North Carolina-Louisiana Prostate Cancer Project (PCaP) (2016) (0)
- Commentary on Randomized phase II trial of first-line treatment with sorafenib vs. interferonα-2a in patients with metastatic renal cell carcinoma (2009) (0)
- Abstract 4944: Regulation of vitamin D 24-hydroxylase gene expression in human prostate cancer by epigenetic mechanisms (2010) (0)
- Activation of a mitochondrial apoptosis pathway induced by calcitriol in combination with ketoconazole and dexamethasone in human prostate cancer PC-3 cells (2006) (0)
- Molecular characterization of brain metastases in patients with metastatic urothelial cancer. (2018) (0)
- Abstract 1288: Molecular features of endothelial cells isolated from benign and malignant prostatic tissues (2010) (0)
- R a n d o mized T rial o f I nfluenza V accine W ith G ranulocyte- Macrophage C olony-Stimulati ng F actor o r P lacebo i n Cancer P atients (2002) (0)
- Additional file 1: of Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing (2016) (0)
- MP-22.11 (2006) (0)
- Abstract B81: Vitamin D and prostate cancer aggressiveness among African and European Americans in the North Carolina-Louisiana Prostate Cancer Project (PCaP) case study cohort (2011) (0)
- Reviews of 3 Clinical Trials (2011) (0)
- Abstract LB-039: 1,25 dihydroxyvitamin D3 and cisplatin combination modulate p73 in bladder cancer (2015) (0)
- Phase I and Pharmacokinetic Study of Weekly Docetaxel , Cisplatin , and Daily Capecitabine in Patientswith Advanced Solid Tumors (2005) (0)
- Abstract #868: 1,25D3 enhances antitumor effects of cisplatin and gemcitabine in human bladder cancer model systems (2009) (0)
- Abstract 583: Inecalcitol, a 14-epi-analogue of 1,25D3, induces growth inhibition through apoptosis and cell cycle arrest in a squamous cell carcinoma model system (2011) (0)
- Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ, University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA (2003) (0)
- Artificial Intelligence is no longer Rocket Science (2018) (0)
- Comprar Vitamin D and Cancer | Trump, Donald L. | 9781441971876 | Springer (2011) (0)
- Abstract 1086: Vitamin D3 increases the response to cisplatin in bladder cancer through VDR and TAp73 pathway crosstalk (2017) (0)
- Wireless Capsule Endoscopy as a Diagnostic Tool and Predictor of Acute and Chronic Graft-Versus-Host Disease: 1354 (2009) (0)
- Can 1H-Nuclear magnetic resonance (NMR) be used for early detection of hepatocellular cancer (HCC)? (2007) (0)
- Disproportionately low plasma and tumor tissue calcitonin (CT) content in advanced medullary thyroid carcinoma (MTC): An unfavorable prognostic sign? (1979) (0)
- Abstract LB-158: P73, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle invasive bladder cancer (MIBC) (2015) (0)
- Do Elderly Patients Get Continuity of Care (1994) (0)
- Phase I Clinical Study with Pharmacokinetic Analysis of 2-ß-o-Ribofuranosylthiazole-4-carboxamide Administered as a Five-Day Infusion1 (2006) (0)
- Commentary on A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation (2009) (0)
- Androgen Deprivation for Men with PSA-Only Failure Following Radical Prostatectomy: When? (2004) (0)
- PD17-04 RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF VITAMIN D3 REPLACEMENT IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER (2021) (0)
- Biological and Clinical Effects of Intravenous Tumor Necrosis Factor-« Administered Three Times Weekly1 (2006) (0)
- Phase I, pharmacokinetic (PK), pharmacodynamic study of paricalcitol [19-nor-1 alpha, 25-(OH)2 D2] in combination with gemcitabine [2',2' difluorodeoxycytidine] in patients with advanced malignancies. (2006) (0)
- Abstract 178: Vitamin D reduces lung cancer progression the N-nitroso-tris-chloroethylurea model of mouse lung squamous cell carcinoma. (2013) (0)
- Patients A Limited Sampling Method for the Estimation of Serum Calcitriol Area under the Curve in Cancer (2003) (0)
- 25(OH) Vitamin D3 Delays Leukemogenesis in an Acute Myeloid Leukemia Murine Model (2014) (0)
- A title for a really great piece of research, just the best, reallly (2016) (0)
- Commentary on Sequential therapy with sorafenib and sunitinib in renal cell carcinoma (2009) (0)
- Hydrocortisone W ith o r W ithout M itoxantrone i n M en W ith Hormone-Refractory P rostate C ancer: R esults o f t he C ancer and L eukemia G roup B 9 182 S tudy (1999) (0)
- Mo1927 Histological Changes Following Sunitinib Therapy in the Woodchuck Model of Hepatitis B Related HCC (2014) (0)
- Survival outcomes and patterns of utilization of cytoreductive nephrectomy in the tyrosine kinase inhibitors (TKI)-era in metastatic clear cell renal cell carcinoma (ccRCC) and non-clear cell renal cell carcinoma (nccRCC): Analyses from the National Cancer Database (NCDB). (2017) (0)
- Journal of Cancer Vitamin D in combination cancer treatment (2019) (0)
- Effect of ketoconazole/hydrocortisone (Keto/HC) on 25 (OH) vitamin D in men with castration-resistant prostate cancer (CRPC). (2011) (0)
- Gynecomastia in Men Following Antineoplastic Therapy (1982) (0)
- by Calcitriol Contributes to Selective Growth Inhibition Tumor-derived Endothelial Cells Epigenetic Silencing of CYP24 in Developmental Biology: Molecular Basis of Cell and (2014) (0)
- Antiproliferative and Proapoptotic Effect of Vitamin D in Bortezomib (B) Resistant Human Myeloma Cell Line (HMCL). (2006) (0)
- Prognostic Factors for Survival in Patients with Recurrent or Metastatic Renal Cell Carcinoma 1 (2006) (0)
- Additional file 5: Table S3. of Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing (2016) (0)
- Exenatide and Pancreatic Cancer : A Case Report and Review of Relevant Literature (2015) (0)
- Additional file 3: Table S1. of Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing (2016) (0)
- Abstract 607: Targeting PIM1 kinase enhances 1,25-dihydroxyvitamin D3-mediated anti-tumor activity in bladder cancer cells (2014) (0)
- Anitcancer Activity of Vitamin D Analogs (1999) (0)
- Contents Vol. 70, 2006 (2007) (0)
- Additional file 4: Table S2. of Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing (2016) (0)
- Modulation of Paclitaxel Antitumor Effects by Calcitriol: Preclinical Studies of Mechanism, Toxicity and Efficacy in Prostate Cancer (2001) (0)
- Commentary on Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer (2009) (0)
- Abstract 879: New serum biomarkers for prostate cancer diagnosis (2014) (0)
- Abstract 942: Protein kinase CK2 contributes to 1, 25-dihydroxyvitamin D3-mediated CYP24A1 gene expression in prostate cancer cells (2011) (0)
- A phase I/II clinical trial of intravenous (I.V.) calcitriol with fixed doses of cisplatin and docetaxel in advanced non-small cell lung cancer. (2012) (0)
- Phase I Clinical Trial and Pharmacokinetic Evaluation of Acodazole (NSC 305884), an Imidazoquinoline Derivative with Electrophysiological Effects on the Heart1 (2006) (0)
- 60 – Reproductive Complications (2014) (0)
- Subject Index Vol. 70, 2006 (2007) (0)
This paper list is powered by the following services:
Other Resources About Donald L. Trump
What Schools Are Affiliated With Donald L. Trump?
Donald L. Trump is affiliated with the following schools: